ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

4:30PM-6:00PM: Abstract Number: 0533

Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity

Abstracts: RA – Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 0553

Stair Climbing Difficulty and Risk of Functional Limitation in Knee Osteoarthritis: A Simple Functional Vital Sign?

Abstracts: Exemplary Interprofessional Research

4:30PM-6:00PM: Abstract Number: 0534

Synovial Transcriptomic Profiles Correlate with Disease Activity in Early Untreated Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 0532

Women with Early Rheumatoid Arthritis Less Likely to Achieve Rapid and Sustainable Remission: Results from the Canadian Early Arthritis Cohort Study

Abstracts: RA – Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease

5:00PM-6:00PM: Abstract Number: PP26

Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life

Patient Perspectives

5:00PM-6:00PM: Abstract Number: PP25

From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective

Patient Perspectives

5:00PM-6:00PM: Abstract Number: 0555

Heterogeneity in Origin and Function of Distinct Human Synovial-tissue Dendritic Cells in Health, Active Rheumatoid Arthritis (RA) and RA in Disease Remission

Abstracts: Innate Immunity

5:00PM-6:00PM: Abstract Number: 0556

Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response

Abstracts: Innate Immunity

5:00PM-6:00PM: Abstract Number: 0554

Loss of Synovial Tissue Macrophage Homeostasis Precedes Rheumatoid Arthritis Clinical Onset

Abstracts: Innate Immunity

5:00PM-6:00PM: Abstract Number: PP24

Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp

Patient Perspectives

5:00PM-6:00PM: Abstract Number: PP23

The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient

Patient Perspectives

5:00PM-6:00PM: Abstract Number: 0557

VEXAS Syndrome Is Characterized by Blood and Tissues Inflammasome Pathway Activation and Monocyte Dysregulation

Abstracts: Innate Immunity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].